Proactive Investors - Run By Investors For Investors

LeanLife shares pop in anticipation of distribution of Omega-3 samples in Europe

Shares rose more than 11% after news that LeanLife’s proprietary Omega-3 product will be distributed to a consumer base of some of the continent’s largest food producers
leanlife omega 3
Samples of LeanLife's Omega-3 products have arrived in Europe for distribution

LeanLife Health Inc (CSE:LLP) announced Tuesday that its first Omega-3 product samples are ready for distribution in Europe.

Shares of LeanLife popped on the news, up 11.1% at C$0.05 by midday Tuesday.

The Vancouver-based company develops proprietary plant-based food products that can be used as food additives or nutraceuticals. It has a patented process to isolate Omega-3 fatty acids from flax seeds.

READ: LeanLife hits new milestone, ships first Omega-3 product samples

LeanLife’s proprietary Omega-3 product will be distributed to a consumer base of some of the continent’s largest producers of bread, pasta, cheese, yogurt and butter.

"With the samples now available for distribution in Europe and confirmation of the quality and specifications of our propriety Omega-3 product underway, our experienced sales and industry expert will soon be visiting some of Europe's largest food producers," said Stan Lis, LeanLife’s CEO.

Recently, a trial application using the Omega-3 product as a substitute for vegetable oil showed negligible difference in taste and quality, LeanLife said in a statement.

The testing resulted in the production of samples which will now be evaluated by SGS, a third-party accredited lab.

According to the extract manufacturer, the company is ready to begin large-scale production and fulfill multiple orders following the validation of samples by buyers.

The global Omega-3 market reached US$33 billion in 2016 and is expected to reach upwards of US$57 billion by 2025, according to a report by Grand View Research Inc.

The company also announced that it has granted stock options to officers, directors and consultants of LeanLife entitling them to purchase a combined total of 3.9 million shares at C$0.05 per share.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

View full LLP profile View Profile

LeanLife Health Timeline

February 07 2019

Related Articles

April 05 2019
Chief executive Peter Butterfield said the company has started 2019 well-positioned for growth after a strong performance in 2018.
Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
June 11 2019
Oncimmune is a specialist in the field of immunodiagnostics

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use